Vicarious Surgical Inc. (NYSE: RBOT) announced on January 12, 2026 that it has successfully completed a December 2025 in‑vivo porcine laboratory study. The lab, conducted with the company’s pre‑de‑V system, involved surgeons performing key steps of a ventral hernia repair, including intraperitoneal onlay mesh placement, monopolar scissors energy delivery, and advanced visualization tests.
The study provided practical data on instrument articulation, system integration, and procedural workflow in a realistic surgical environment. Feedback from the surgeons and performance metrics are being used to refine the system’s design and inform verification planning, bringing the company closer to a design freeze slated for the end of 2026.
This milestone marks the first in‑vivo animal test with the integrated system architecture, a critical step in reducing technical risk and accelerating the path to regulatory submission and eventual clinical use. The data generated will shape the next phase of development and support the company’s strategy to deliver a production‑equivalent robotic platform before initiating a pivotal clinical trial.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.